Role of Antioxidant Gene Polymorphisms in Risk and Prognosis of Chronic Myeloid Leukemia

  1. Sailaja Kagita ,
  2. Raghunadharao Digumarti ,
  3. Sadhashivudu Gundeti

Vol 6 No 1 (2021)

DOI 10.31557/apjcb.2021.6.1.27-36

Submitted: Dec 21, 2020

Published: Mar 21, 2021

Abstract

Introduction: We aimed to investigate the possible role of antioxidant enzyme polymorphisms CAT -21A/T (rs7943316), CAT -262C/T (rs1001179), GPX1 -198C/T (rs1050450), MPO -463G/A (rs2333227), GSTM1 (rs366631) & GSTT1 (rs17856199) with susceptibility to chronic myeloid leukemia (CML) and their association with tyrosine kinase inhibitor (TKI, imatinib) response.
Methods: Six single nucleotide polymorphisms (SNPs) in antioxidant enzyme genes were genotyped in a total of 325 samples, of which 125 were from CML patients and 200 from healthy controls. The SNPs were correlated with various confounding variables lke BCR-ABL1 levels and tyrosine kinase domain mutation status in CML patients.
Results: Genotyping results revealed statistically significant associations with CAT -21A/T (p=0.037) and GPX1 -198C/T (p=<0.0001) polymorphisms with risk of CML. No associations were observed between CAT -262C/T, MPO -463G/A, GSTM1 & GSTT1 polymorphisms and CML. The CAT -21A/T polymorphism conferred 2.95 folds increased risk of CML under co-dominant model (p=0.024) and 2.51 folds risk under dominant models (p=0.05). In addition, the haplotypes of CAT -21A/T and -262C/T polymorphisms, ATCC and ATCT conferred higher incidence of CML risk by 2.67 times (p=0.05) and 2.99 times (p=0.045). The GPX1 -198C/T polymorphism conferred significantly increased risk of CML under co-dominant model [CC vs CT (p=<0.0001), CC vs TT (p=<0.0001)] and dominant models [CC vs CT+TT (p=<0.0001)]. The heterozygous GPX1 CT genotype frequency significantly elevated in poor molecular responders (p=0.005) and TKD mutation carriers (p=0.114) as compared to respective groups.
Conclusions: Our results suggest that the reduced activity of antioxidant enzymes caused by the CAT -21A/T and GPX1-198C/T polymorphisms might contribute to increased risk of CML. In addition, the GPX1-198C/T polymorphism was associated with poor molecular response and acquired TKD mutations. Hence, the present study indicates that defective antioxidant defense system might have a strong influence on CML susceptibility and TKI (imatinib) response through oxidative stress.

Introduction

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder of myeloid precursors, characterized by the presence of Philadelphia (Ph) chromosome, which results from a reciprocal chromosomal translocation t (9;22), leading to the BCR-ABL1 fusion gene. The BCR-ABL1 gene can modulate DNA repair mechanisms, cell cycle checkpoints, Bcl2 proteins and enhances reactive oxygen species (ROS) generation, which may contribute to genomic instability and resistance towards tyrosine kinase inhibitor (TKI) treatment [1-3]. The intrinsic regulation of ROS is one of the mechanisms associated with multidrug resistance and maintenance of cancer stemness [4-5]. Previous studies have demonstrated that oxidative DNA damage induced by higher levels of ROS has been associated with initiation and progression of solid tumors and hematological malignancies [6-9]. Antioxidant enzymes such as catalase (CAT), manganese superoxide dismutase (MnSOD), glutathione peroxidase 1 (GPX1), myeloperoxidase (MPO) and glutathione-S-transferases (GSTs) balance ROS levels and defend cells against oxidative stress. Most of these antioxidant enzymes are highly polymorphic. Genetic variations of these antioxidant enzymes with altered enzymatic activity may contribute to the imbalance of ROS production and scavenging [10-11]. The activity of several antioxidant enzymes was noted to be reduced in CML patients [12]. Several studies demonstrated that polymorphisms in antioxidant enzymes (CAT, MnSOD, GPX1, MPO & GSTs) might be associated with susceptibility to various solid tumors [13-15] and hematological malignancies [16-20].

Hence, the present study aimed to investigate the possible role of polymorphisms in antioxidant enzyme polymorphisms: Catalase (CAT) -21A/T & -262C/T, Glutathione peroxidase 1 (GPX1) -198C/ T, Myeloperoxidase (MPO) -463G/A, deletion of Glutathione S-Transferase M1 & T1 (GSTM1 & GSTT1) with susceptibility to chronic myeloid leukemia and their association with TKI (imatinib) response.

Materials and Methods

The present study included 325 samples, out of which 125 are from CML patients and 200 were from age & gender matched controls without a family history of any cancer. The inclusion criteria for patients included Ph+ve CML cases with confirmed diagnosis, on TKI treatment and TKI refractory cases regardless of age, gender or race. The study was approved by the institutional ethics committee and an informed consent was obtained from patients participating in the study. Blood samples (6mL in EDTA vaccutainer) were collected from both CML patients and controls. Genomic DNA was extracted from blood samples using non-enzymatic rapid salting-out method. The purity & concentration of DNA samples were checked on Nanodrop1000 and further these DNA samples were subjected for analysis of SNPs in antioxidant enzyme genes.

Genotyping of antioxidant gene SNPs

Genotyping of CAT -21A/T (rs7943316), CAT -262C/T (rs1001179), GPX1 (-198C/T rs1050450) and MPO (-463G/A rs2333227) was performed by PCR-RFLP (polymerase chain reaction - restriction fragment length polymorphism) method. The null/deletion polymorphism in GSTM1 & GSTT1 genes (rs366631 & rs17856199) were performed by multiplex polymerase chain reaction followed by agarose gel electrophoresis. The primers used for amplification and restriction enzymes for RFLP analysis are listed in Table 1.

Table 1. Primer Sequences used for Analysis of Polymorphisms in Anti oxidant Enzyme Genes.

Gene SNP Primer sequence Product size Restriction enzyme
CAT -21A/T 5′- AATCAGAAGGCAGTCCTCCC-3′ 250bp HinfI
(rs7943316) 5′- TCGGGGAGCACAGAGTGTAC-3′
CAT -262C/T 5′- AGAGCCTCGCCCCGCCGGACCG-3′ 185bp SmaI
(rs1001179) 5′- TAAGAGCTGAGAAAGCATAGCT-3′
GPX -198C/T 5′- TCCAGACCATTGACATCGAG-3′ 222bp ApaI
(rs1050450) 5′- ACTGGGATCAACAGGACCAG-3′
MPO -463G/A 5′- CGGTATAGGCACACAATGGTGAG-3′ 350bp SsiI
(rs2333227) 5′- CAATGGTTCAAGCGATTCTTC-3′
GSTM1 Deletion 5′- GAACTCCCTGAAAAGCTAAAGC-3′ 219bp
(rs366631) 5′- GTTGGGCTCAAATATACGGTGG-3′
GSTT1 Deletion 5′- TTCCTTACTGGTCCTCACATCTC-3′ 480bp
(rs17856199) 5′- TCACCGGATCACGGCCAGCA-3′
Beta globin 5′- ACACAACTGTGTTCACTAGC-3′ 299bp
5′- CAACTTCATCCACGTTCACC-3′

The CAT (-21A/T & -262C/T), GPX1 (-198C/T) and MPO (-463G/A) polymorphism were determined by digesting the PCR amplified products with HinfI, SmaI, ApaI and SsiI restriction enzymes (Table 1).

Statistical analysis

Chi square and multivariate analysis tests were calculated to test the significance of genotype association with the occurrence of CML and its prognosis. All the p values were two sided and the level of significance was taken as p <0.05. Statistical analyses were performed using the GraphPad Prism software version 6.0 (San Diego, CA) and online VassarStats software. Haplotype and pairwise linkage disequilibrium was calculated using Haploview version 4.2 and cox regression analysis by SPSS version 22 software.

Results

Baseline characteristics (Table 2)

The demographic and clinical characteristics of CML patients are presented in Table 2.

Table 2. Patient Baseline Characteristics (n=125).

No %
Gender
Males 77 61.6
Females 48 38.4
Age at onset
≤ 42 years 60 48
> 42 years 65 52
Phase
Chronic 102 81.6
Acute 23 18.4
Sokal risk
Low 47 37.6
Intermediate 33 26.4
High 45 36
Hasford risk
Low 49 39.2
Intermediate 49 39.2
High 27 21.6
EUTOS risk
Low 90 72
High 35 28
BCR-ABL1 levels
< 10% 40 32
> 10% 85 68
TKD mutations
Presence 30 24
Absence 95 76
Present status
Follow-up 104 83.2
Deceased 21 16.8

The median age at diagnosis of CML was 42 years (range 12 to 89 years) and a male preponderance was observed with a male to female ratio of 1.6:1. Of the 125 patients, 102 cases presented in chronic phase, 13 in accelerated phase and 10 in blast crisis phase of CML.

Prognostic scores like Sokal, Hasford, and EUTOS (European Treatment Outcome Study) were calculated for all patients using baseline hematological variables [21]. With Sokal risk scoring, 37.6% of patients had low risk and 62.4% had intermediate + high risk. With respect to Hasford risk score, 39.2% had low risk and 60.80% had intermediate + high risk. When EUTOS risk scores were considered, 72.0% of patients were presented with low risk and 28% with high EUTOS risk. Majority of patients were on imatinib (IM) treatment, nearly 42.4% of patients received higher IM doses (600mg/ 800mg), 16.8% on IM standard dose (400mg), 16.0% on other drugs (2nd generation TKIs or on clinical trials), 16.8% deceased and 8% are newly diagnosed.

Median follow-up of these patients for a period of 40 median months revealed that 20.8% had optimal response to imatinib and 79.02% of patients lost respone which might be either due to loss of complete hematological response (CHR), complete cytogenetic response (CCyR), major molecular response (MMR) or presence of TKD mutations.

Correlation with CAT -21A/T polymorphism (Table 3)

The CAT -21A/T genotyping results revealed that heterozygous AT genotype frequency was observed to be significantly increased in CML patients compared to controls (p=0.037). This polymorphism was significantly assciated with increased risk of CML. With respect to molecular response, homozygous TT genotype and T allele frequencies were elevated in non-responders i.e., patients having higher BCR-ABL1 expression levels (44.70%, 0.705) compared to responders i.e., patients having lower levels (35.0%, 0.625) (p=0.259). Heterozygous AT genotype frequency was found to be slightly increased in TKD mutation carriers (p=0.571) and in deceased group of patients (p=0.548) when compared to respective groups. No differences were found with either of the prognostic risk scores: Sokal, Hasford or EUTOS.

Table 3. Genotyping of CAT -21A/T Polymorphism.

Genotype frequency Allele frequency p value
AA AT TT Total A T
CML cases 7 (5.6%) 66 (52.8%) 52 (41.6%) 125 0.32 0.68 0.037
Controls 26 (13.0%) 83 (41.5%) 91 (45.5%) 200 0.337 0.662
BCR-ABL1 levels
< 10% 4 (10.0%) 22 (55.0%) 14 (35.0%) 40 0.375 0.625 0.259
> 10% 3 (3.52%) 44 (51.76%) 38 (44.70%) 85 0.294 0.705
TKD mutations
Presence 2 (6.66%) 18 (60.0%) 10 (33.33%) 30 0.366 0.633 0.571
Absence 5 (5.26%) 48 (50.52%) 42 (44.21%) 95 0.305 0.694
Present status
Follow-up 5 (4.80%) 54 (51.92%) 45 (43.26%) 104 0.307 0.692 0.548
Deceased 2 (9.52%) 12 (57.14%) 7 (33.33%) 21 0.38 0.619

The CAT -21A/T polymorphism showed statistically significant association with risk of CML and conferred 2.95 folds increased risk of CML under codominant (AA vs AT) model (OR=2.953, 95% CI: 1.206-7.228, p=0.024) and 2.51 folds risk under dominant (AA vs AT+TT) models (OR=2.518, 95% CI: 1.058-5.992, p=0.05), whereas overdominant model (AT vs AA+TT) was found to be protective against CML (OR=0.632, 95% CI: 0.404-0.994, p=0.060) (Table 4).

Table 4. Distribution of Odds Ratios between Cases vs Controls with CAT -21A/T Polymorphism.

CML patients (n=125) Controls (n=200) OR (95% CI) p value
Codominant
AA 7 (5.6%) 26 (13.0%)
AT 66 (52.8%) 83 (41.5%) 2.953 (1.206-7.228) 0.024
TT 52 (41.6%) 91 (45.5%) 2.122 (0.861-5.228) 0.145
Dominant
AA 7 (5.44%) 26 (13.0%)
AT+TT 118 (94.55%) 174 (7.0%) 2.518 (1.058-5.992) 0.050
Recessive
AT+AA 73 (58.50%) 109 (54.5%)
TT 52 (41.49%) 91 (45.5%) 0.853 (0.543-1.340) 0.565
Overdominant
AT 66 83
AA+TT 59 117 0.632 (0.404-0.994) 0.06

Correlation with CAT -262C/T polymorphism (Table 5)

There was no significant difference observed between cases and controls (p=0.711), molecular response (p=0.865) and presence or absence of TKD mutations (p=0.708) with CAT-262C/T polymorphism. This polymorphism was not assciated with risk of CML. Whereas the homozygous CC genotype and C allele frequencies were found to be elevated in the deceased group (71.42%, 0.857) compared to those patients on follow-up (50.0%; 0.711) (p=0.139). The prognostic risk scores were not associated with this polymorphism.

Table 5. Genotyping of CAT -262 C/T Polymorphism.

    Genotype frequency       Allele frequency p value
  CC CT TT Total C T  
CML cases 67 (53.6%) 50 (40.0%) 8 (6.4%) 125 0.736 0.264 0.711
Controls 116 (58.0%) 71 (35.5%) 13 (6.5%) 200 0.757 0.242  
BCR-ABL1 levels              
< 10% 21 (52.5%) 17 (42.5%) 2 (5.0%) 40 0.737 0.262 0.865
> 10% 46 (54.11%) 33 (38.82%) 6 (7.05%) 85 0.735 0.264  
TKD mutations              
Presence 16 (53.33%) 13 (43.33%) 1 (3.33%) 30 0.75 0.25 0.708
Absence 51 (53.68%) 37 (38.94%) 7 (7.36%) 95 0.731 0.268  
Present status              
Follow-up 52 (50.0%) 44 (42.30%) 8 (7.69%) 104 0.711 0.288 0.139
Deceased 15 (71.42%) 6 (28.57%) 0 21 0.857 0.142  

Haplotype analysis of the CAT gene (Table 6)

The haplotype analysis of the CAT gene polymorphisms (-21A/T and -262C/T) were performed and represented in Table 6.

Table 6. Distribution of CAT (-21A/T and -262C/T) Halotypes and their Correlation with Risk of CML.

Haplotypes CML patients (n=125) Controls (n=200) OR (95% CI) p value
AACC 7 (5.6%) 25 (12.5%)
AACT 0 1 (0.5%)
AATT 0 0
ATCC 39 (31.2%) 52 (26.0%) 2.678 (1.051-6.825) 0.05
ATCT 26 (20.8%) 31 (15.5%) 2.995 (1.116-8.037) 0.045
ATTT 1 (0.8%) 0
TTCC 21 (16.8%) 40 (20.0%) 1.875 (0.696-5.049) 0.31
TTCT 24 (19.2%) 38 (19.0%) 2.556 (0.845-6.019) 0.157
TTTT 7 (5.6%) 13 (6.5%) 1.923 (0.554-0.298) 0.475

The haplotypes ATCC and ATCT conferred higher incidence of CML risk by 2.67 times (OR=2.678, 95% CI: 1.051-6.825, p=0.05) and 2.99 times (OR=2.995,95% CI: 1.116-8.037, p=0.045).

Correlation with GPX1 -198C/T polymorphism (Table 7)

The heterozygous CT genotype and T allele frequencies were significantly increased in CML patients compared to controls (p=<0.0001). With respect to molecular response and TKD mutation status, the heterozygous CT genotype frequency was observed to be significantly elevated in poor molecular responders group (patients having higher BCR-ABL1 levels) (p=0.005), TKD mutation carriers (p=0.114) and in patients of advanced phases (p=0.292) compared to respective groups. With respect to present status, the frequencies of TT genotype and T alleles were found to be slightly increased in deceased group of patients (23.80%; 0.619) compared to those on follow-up (17.30%; 0.552) (p=0.404). No significant variations were found with prognostic risk scores.

Table 7. Genotyping of GPX1 -198C/T Polymorphism.

    Genotype frequency       Allele frequency p value
  CC CT TT Total C T  
CML cases 7 (5.6%) 95 (76.0%) 23 (18.4%) 125 0.436 0.564 <0.0001
Controls 62 (31.15%) 115 (57.78%) 22 (11.05%) 199 0.6 0.399  
BCR-ABL1 levels              
< 10% 6 (15.0%) 26 (65.0%) 8 (20.0%) 40 0.475 0.525 0.005
> 10% 1 (1.17%) 69 (81.17%) 15 (17.64%) 85 0.417 0.582  
TKD mutations              
Presence 1 (3.33%) 27 (90.0%) 2 (6.66%) 30 0.483 0.516 0.114
Absence 6 (6.31%) 68 (71.57%) 21 (22.10%) 95 0.421 0.578  
Present status              
Follow-up 7 (6.73%) 79 (75.96%) 18 (17.30%) 104 0.447 0.552 0.404
Deceased 0 16 (76.19%) 5 (23.80%) 21 0.38 0.619  

In addition, the GPX1 -198C/T polymorphism increased the risk of CML under codominant model [CC vs CT (OR=7.316, 95% CI: 3.198-17.736, p=<0.0001), CC vs TT (OR=9.259, 95% CI: 3.489-24.571, p=<0.0001)] and dominant models [CC vs CT+TT (OR=7.628, 95% CI: 3.362-17.310, p=<0.0001)], whereas overdominant model (CT vs CC+TT) was found to be protective against CML (OR=0.432, 95% CI: 0.262-0.711, p=0.001) (Table 8).

Table 8. Distribution of Odds Ratios between Cases vs Controls with GPX1 -198C/T Polymorphism.

Cases Controls OR (95% CI) p value
Codominant
CC 7 (5.6%) 62 (31.15%)
CT 95 (76.0%) 115 (57.78%) 7.316 (3.198-17.736) <0.0001
TT 23 (18.4%) 22 (11.05%) 9.259 (3.489-24.571) < 0.0001
Dominant
CC 7 (55.10%) 62 (58.0%) 7.628 (3.362-17.310) < 0.0001
CT+TT 118 (44.89%) 137 (42.0%)
Recessive
CT+CC 102 (93.87%) 177 (93.5%) 1.814 (0.963-3.417) 0.089
TT 23 (6.12%) 22 (6.5%)
Overdominant
CT 95 115
CC+TT 30 84 0.043 (0.262-0.711) 0.001

Correlation with MPO -463G/A polymorphism (Table 9)

The MPO -463G/A polymorphism demonstrated no significant association between cases and controls (p=0.494), nor with either of the confounding variables like molecular response (p=0.465), TKD mutation status (p=0.392), present status (p=0.767) and prognostic risk scores.

Table 9. Genotyping of MPO -G463A Polymorphism.

    Genotype frequency     Allele frequency   p value
  GG GA AA Total G A  
CML cases 90 (72.0%) 33 (26.4%) 2 (1.6%) 125 0.852 0.148 0.494
Controls 135 (67.5%) 58 (29.0%) 7 (3.5%) 200 0.82 0.18  
BCR-ABL1 levels              
< 10% 26 (65.0%) 13 (32.5%) 1 (2.5%) 40 0.812 0.187 0.465
> 10% 64 (75.29%) 20 (23.52%) 1 (1.17%) 85 0.87 0.129  
TKD mutations              
Presence 19 (63.33%) 10 (33.33%) 1 (3.33%) 30 0.8 0.2 0.392
Absence 71 (74.73%) 23 (24.21%) 1 (1.05%) 95 0.868 0.131  
Present status              
Follow-up 74 (71.15%) 28 (26.92%) 2 (1.92%) 104 0.846 0.153 0.767
Deceased 16 (76.15%) 5 (23.80%) 0 21 0.88 0.119  

Correlation with GSTM1 & GSTT1 null/deletion polymorphism (Table 10)

No significant association observed with GSTM1 null polymorphism between cases and controls, molecular response, presence or absence of TKD mutations. Whereas GSTM1 presence genotype (M1) was found to be elevated in deceased group (80.95%) compared to those on follow-up (66.34%) (p=0.289).

Table 10. Genotyping of GSTM1 & GSTT1 Deletion Polymorphism.

  Genotype frequencies            
  T1 T0 p value M1 M0 p value Total
CML cases 97 (77.6%) 28 (22.4%) 0.193 86 (68.8%) 39 (31.2%) 1 125
Controls 168 (84.0%) 32 (16.0%)   136 (68.0%) 64 (32.0%)   200
BCR-ABL1 levels              
< 10% 35 (87.5%) 5 (12.5%) 0.111 27 (67.5%) 13 (32.5%) 1 40
> 10% 62 (72.94%) 23 (27.05%)   59 (69.41%) 26 (30.58%)   85
TKD mutations              
Presence 27 (90.0%) 3 (10.0%) 0.105 22 (73.33%) 8 (26.66%) 0.698 30
Absence 70 (73.68%) 25 (26.31%)   64 (67.36%) 31 (32.63%)   95
Present status              
Follow-up 80 (76.92%) 24 (23.07%) 0.92 69 (66.34%) 35 (33.65%) 0.289 104
Deceased 17 (80.95%) 4 (19.04%)   17 (80.95%) 4 (19.04%)   21

With GSTT1 null polymorphism, the GSTT1 null genotype frequency slightly increased in cases compared to controls (22.4%; 16.0%) (p=0.193). When the results are stratified with confounding variables, the GSTT1 null genotype frequency was found to be higher in non-responders (27.05%; 12.5%) and in patients not carrying TKD mutations (26.31%; 10.0%) compared to respective groups. There was no difference was observed between follow-up and deceased group of patients with GSTT1 null genotype.

No significant differences were found between GSTM1 & GSTT1 null/deletion polymorphisms and prognostic risk scores.

Haplotype, Linkage Disequilibrium (LD) and Cox Regression analysis:

The haplotype and pairwise epistasis among six SNPs did not revealed any significant association, hence data not presented. The linkage disequilibrium (LD) analysis revealed that the two CAT -21A/T (rs1001179) and CAT -262 C/T (rs7943316) exhibited high LD (D’=0.9). Since the two SNPs are located on chromosome 1, the observed significant LD might be attributed to the physical proximity. None of the other SNP combinations showed significant LD with D’<0.5 (Figure 1).

Figure 1. LD plot.

Cox regression analysis of SNPs with BCR-ABL1 levels revealed no significant association.

Discussion

In the present study, we investigated the association of the genetic variations of the antioxidant enzymes: CAT (-21A/T, rs7943316 & -262C/T, rs1001179), GPX1 (-198C/T, rs1050450), MPO (-463G/A, rs2333227) and GSTM1 (rs366631) & GSTT1 genes (rs17856199) with susceptibility to CML and their correlation with imatinib (TKI) response.

Our results revealed statistically significant association of CAT -21A/T (p=0.037) and GPX1 -198C/T (p<0.0001) polymorphisms with the risk of CML. No significant associations were observed between CAT -262C/T (p=0.711), MPO -463G/A (p=0.494), GSTM1 and GSTT1 null/deletion polymorphisms (p=1; p=0.193) and CML. Catalase is an endogenous antioxidant enzyme involved in ROS neutralizing pathways and prevents cellular injury from ROS [22]. Two polymorphisms: CAT-21A/T with altered gene expression pattern [23] and CAT -262C/T with lower CAT enzyme activity [24] may alter ROS detoxification and increase oxidative stress, implicating oxidative DNA damage and modulating disease risk [25]. In the present study, the CAT -21A/T polymorphism was significantly associated with increased risk of CML (p=0.037).

The stratified genotyping results with various confounding variables revealed that the homozygous variant TT genotype increased in non responders (p=0.259) and the heterozygous AT genotype frequency in TKD mutation carriers (p=0.571) and in deceased (p=0.548) group of patients. In addition, the codominant model (AA vs AT) (p=0.024) and dominant models (combined AT and TT genotypes) (p=0.05) presented significant association with increased risk of CML when compared with AA homozygote. Whereas Liu et al (2016) reported an increased cancer risk with recessive model and homozygote model [26]. This indicates that variant T allele with lower catalase activity and thus increased levels of ROS may contribute to genomic instability and increased risk of cancer. Earlier studies reported no significant associations with the risk of colorectal cancer [27], gastric cancer (GC) and hepatocellular carcinoma (HCC) [13].

In our study, we found no evidence of the CAT -262 C/T polymorphism with CML risk or its association with confounding variables. Our results are in accordance with earlier studies that reported no significant association with risk of hepatocellular carcinoma [28], breast cancer [29], and gastric cancer [30]. Previous other studies showed significant increased risk of cervical cancer [15], breast cancer [31], hepatocellular carcinoma [32] and prostate cancer [33]. Whereas others reported that -262C/T polymorphism was a protective factor with respect to chronic myeloid leukemia [19] and hepatocellular carcinoma susceptibility [14-17].

GPX1 is a key enzyme of the antioxidative system that detoxifies peroxide radicals and lipid hydroperoxides. The -198C/T (Pro200Leu) polymorphism in GPX1 is associated with reduced enzyme activity [34-35]. Previous studies reported that higher GPX1 activity is required to counterbalance the ROS levels and related damage occurring during initiation or progression of the cancer [36-39]. We obseved statistically significant association of the homozygous variant TT genotype with CML risk (p=<0.0001). The stratified results of confounding variables presented the significant association of GPX1-198 C/T polymorphism with poor molecular response (p=0.005) and acquired TKD mutations (p=0.114). In addition, the codominant (CC vs CT and CC vs TT) and dominant (CC vs CT+TT) models conferred increased risk of CML when compared with CC homozygote (p=<0.0001). Our results were in accordance with others findings on breast cancer [39-41], bladder cancer [42] and lung cancer [43]. This indicates that the variant Leu allele with reduced enzyme activity might increase ROS levels thereby induced oxidative DNA damage and increased susceptibility to cancer. Whereas other studies failed to find an association of GPX1 -198C/T polymorphism with the risk of CML [19], breast cancer [44-45] and prostate cancer [46].

Glutathione S-transferases (GSTs) are involved in detoxification of a wide range of carcinogens and ROS thereby offering protection against oxidative DNA damage. GST enzymes are polymorphic, which may contribute to the inter-individual variability in the response to oxidative stress suggesting its role in carcinogenesis and risk for cancer. In the present study, the GSTM1 and GSTT1 null/deletion polymorphisms were not associated with risk of CML. Our results are similar with earlier studies on CML [20]. Previous studies on the GSTT1 null polymorphism reported positive association with risk of CML [47-50] and AML [20]. Earlier studies on GSTM1 null polymorphism showed no association the risk of CML [50], AML [51] and breast cancer [52].

Myeloperoxidase (MPO) is an endogenous oxidant enzyme that activates carcinogens [53]. A single nucleotide polymorphism in the promoter region of the MPO gene, G-463A (rs2333227) has been associated with reduced mRNA expression and transcriptional activity and subsequent decreased metabolic activation of procarcinogens [54]. In the present study, no evidence of MPO -463G/A polymorphism with the risk of CML was observed. Our results were in accordance with earlier studies on ALL [55], AML [56] and breast cancer [57]. Whereas others reported that the A allele with reduced MPO activity and ROS production has been associated with decreased risk of breast cancer [58], lung cancer [59] and prostate cancer [60].

In conclusion, our results suggest that the reduced activity of antioxidant enzymes caused by the CAT -21A/T and GPX1-198C/T polymorphisms might contribute to increased risk of CML. In addition, the GPX1-198C/T polymorphism was associated with poor molecular response and acquired TKD mutations. Hence, the present study indicates that defective antioxidant defense system might have a strong influence on CML susceptibility and TKI (imatinib) response through oxidative stress.

Acknowledgments

The authors would be grateful to the participants.

Financial support

This work was partially supported through a grant by Science and Engineering Research Board (SERB), Startup Research Grant for young Scientists, Government of India (Dr. Sailaja Kagita).

Conflicts of interest

There are no conflicts of interest.

References

  1. The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells Sattler Martin, Verma Shalini, Shrikhande Gautam, Byrne Christopher H., Pride Yuri B., Winkler Thomas, Greenfield Edward A., Salgia Ravi, Griffin James D.. Journal of Biological Chemistry.2000;275(32). CrossRef
  2. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells Nieborowska-Skorska M, Flis S, Skorski T. Leukemia.2014;28(12). CrossRef
  3. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T. Leukemia.2012;27(3). CrossRef
  4. Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities Kuo Macus Tien. Antioxidants & Redox Signaling.2009;11(1). CrossRef
  5. Reactive oxygen species and cancer paradox: To promote or to suppress? Galadari Sehamuddin, Rahman Anees, Pallichankandy Siraj, Thayyullathil Faisal. Free Radical Biology and Medicine.2017;104. CrossRef
  6. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells Chan David W., Liu Vincent W.S., Tsao George S.W., Yao Kwok-Ming, Furukawa Toru, Chan Karen K.L., Ngan Hextan Y.S.. Carcinogenesis.2008;29(9). CrossRef
  7. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells Liu Ling-Zhi, Hu Xiao-Wen, Xia Chang, He Jie, Zhou Qiong, Shi Xianglin, Fang Jing, Jiang Bing-Hua. Free Radical Biology and Medicine.2006;41(10). CrossRef
  8. Hydrogen peroxide sensing, signaling and regulation of transcription factors Marinho H. Susana, Real Carla, Cyrne Luísa, Soares Helena, Antunes Fernando. Redox Biology.2014;2. CrossRef
  9. Dual effect of oxidative stress on leukemia cancer induction and treatment Udensi Udensi K, Tchounwou Paul B. Journal of Experimental & Clinical Cancer Research.2014;33(1). CrossRef
  10. Alterations of Antioxidant Enzyme Expression in Response to Hydrogen Peroxide Röhrdanz Elke, Kahl Regine. Free Radical Biology and Medicine.1998;24(1). CrossRef
  11. Effect of Free Radicals & Antioxidants on Oxidative Stress: A Review Shinde Ashok, Ganu Jayashree, Naik Pankaja. Journal of Dental and Allied Sciences.2012;1(2). CrossRef
  12. Anemia and antioxidant defence of the red blood cells Kumerova A, Lece A, Skesters A, Silova A, Petuhovs V. Mater Med Pol.1998;30(1-2):12-5.
  13. No Association between Catalase Gene Polymorphism and Gastric Carcinoma and Hepatocellular Carcinoma in Koreans Lee Ji Hyun, Park Ran Young, Lee Chang Soo, Jeoung Euh Jun, Nam Su Youn, Lee Jae Gun, Han Kye Young, Lee Hee Jae, Chung Joo Ho, Ahn Yun Gul, Yim Sung Vin, Cho Jae Young, Park Yeon Hee. Cancer Research and Treatment.2002;34(6). CrossRef
  14. A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis Nahon Pierre, Sutton Angela, Rufat Pierre, Charnaux Nathalie, Mansouri Abdellah, Moreau Richard, Ganne-Carrié Nathalie, Grando-Lemaire Véronique, N’Kontchou Gisèle, Trinchet Jean-Claude, Pessayre Dominique, Beaugrand Michel. Journal of Hepatology.2012;56(2). CrossRef
  15. The role of CYBA (p22phox) and catalase genetic polymorphisms and their possible epistatic interaction in cervical cancer Castaldo Stephanie Anais, da Silva Alda Pereira, Matos Andreia, Inácio Ângela, Bicho Manuel, Medeiros Rui, Alho Irina, Bicho Maria Clara. Tumor Biology.2014;36(2). CrossRef
  16. Jab1/Csn5–Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress Zhou Fuling, Pan Yunbao, Wei Yongchang, Zhang Ronghua, Bai Gaigai, Shen Qiuju, Meng Shan, Le Xiao-Feng, Andreeff Michael, Claret Francois X.. Clinical Cancer Research.2017;23(15). CrossRef
  17. Genetic polymorphisms in antioxidant enzyme genes and susceptibility to hepatocellular carcinoma in Chinese population: a case-control study Su Song, He Kai, Li Jing, Wu Jiali, Zhang Mengyu, Feng Chunhong, Xia Xianming, Li Bo. Tumor Biology.2015;36(6). CrossRef
  18. Glutathione-S-transferase polymorphism and acute lymphoblastic leukemia (ALL) in north Indian children: a case–control study and meta-analysis Moulik Nirmalya Roy, Parveen Farah, Kumar Archana, Agrawal Suraksha. Journal of Human Genetics.2014;59(9). CrossRef
  19. CAT, GPX1, MnSOD, GSTM1, GSTT1, andGSTP1Genetic Polymorphisms in Chronic Myeloid Leukemia: A Case-Control Study Bănescu Claudia, Trifa Adrian P., Voidăzan Septimiu, Moldovan Valeriu G., Macarie Ioan, Benedek Lazar Erzsebeth, Dima Delia, Duicu Carmen, Dobreanu Minodora. Oxidative Medicine and Cellular Longevity.2014;2014. CrossRef
  20. Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A Löffler Harald, Bergmann Jörg, Hochhaus Andreas, Hehlmann Rüdiger, Krämer Alwin. Blood.2001;98(13). CrossRef
  21. Calculation of Relative Risk of CML Patients. European LeukemiaNet (ELN) 2006 Baccarani . https://www.leukemia-net.org/content/leukemias/cml/euro_and_sokal_score/index_eng.html..
  22. Catalase enzyme mutations and their association with diseases Góth László, Rass Péter, Páy Anikó. Molecular Diagnosis.2004;8(3). CrossRef
  23. Associations between Catalase Phenotype and Genotype: Modification by Epidemiologic Factors Ahn J.. Cancer Epidemiology Biomarkers & Prevention.2006;15(6). CrossRef
  24. Polymorphism of catalase gene promoter in Romanian patients with diabetic kidney disease and type 1 diabetes Panduru NM, Mota E, Mota M. Rom J Intern Med.2010;48:81-88.
  25. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels Forsberg Lena, Lyrenäs Louise, Morgenstern Ralf, de Faire Ulf. Free Radical Biology and Medicine.2001;30(5). CrossRef
  26. Two common functional catalase gene polymorphisms (rs1001179 and rs794316) and cancer susceptibility: evidence from 14,942 cancer cases and 43,285 controls Liu Kang, Liu Xinghan, Wang Meng, Wang Xijing, Kang Huafeng, Lin Shuai, Yang Pengtao, Dai Cong, Xu Peng, Li Shanli, Dai Zhijun. Oncotarget.2016;7(39). CrossRef
  27. Association of Catalase Genotype with Oxidative Stress in the Predication of Colorectal Cancer modification by epidemiological factors Chang D, Hu ZL, Zhang L. Biomed Environ Sci.2012;25(2):156-162. CrossRef
  28. Association Between Catalase Gene Polymorphisms and Risk of Chronic Hepatitis B, Hepatitis B Virus-Related Liver Cirrhosis and Hepatocellular Carcinoma in Guangxi Population Liu Yanqiong, Xie Li, Zhao Jiangyang, Huang Xiuli, Song Liuying, Luo Jingrong, Ma Liping, Li Shan, Qin Xue. Medicine.2015;94(13). CrossRef
  29. Genetic Polymorphism of CAT C-262 T and Susceptibility to Breast Cancer, a Case–Control Study and Meta-Analysis of the Literatures Saadat Mostafa, Saadat Shekoofeh. Pathology & Oncology Research.2014;21(2). CrossRef
  30. Association of CAT C-262T and SOD1 A251G single nucleotide polymorphisms susceptible to gastric cancer Ebrahimpour S, Saadat I. Mol Biol Res Commun.2014;3(4):223-229.
  31. Associations between Breast Cancer Risk and the Catalase Genotype, Fruit and Vegetable Consumption, and Supplement Use Ahn Jiyoung, Gammon Marilie D., Santella Regina M., Gaudet Mia M., Britton Julie A., Teitelbaum Susan L., Terry Mary Beth, Nowell Susan, Davis Warren, Garza Cutberto, Neugut Alfred I., Ambrosone Christine B.. American Journal of Epidemiology.2005;162(10). CrossRef
  32. Polymorphisms in antioxidant defence genes and susceptibility to hepatocellular carcinoma in a Moroccan population Ezzikouri Sayeh, Feydi Abdellah Essaid El, Afifi Rajae, Benazzouz Mustapha, Hassar Mohammed, Pineau Pascal, Benjelloun Soumaya. Free Radical Research.2009;44(2). CrossRef
  33. Oxidative Stress–Related Genetic Variants, Pro- and Antioxidant Intake and Status, and Advanced Prostate Cancer Risk Geybels Milan S., van den Brandt Piet A., van Schooten Frederik J., Verhage Bas A.J.. Cancer Epidemiology Biomarkers & Prevention.2014;24(1). CrossRef
  34. Phenotype Determination of a Common Pro-Leu Polymorphism in Human Glutathione Peroxidase 1 Forsberg Lena, de Faire Ulf, Marklund Stefan L, Andersson Peter M, Stegmayr Birgitta, Morgenstern Ralf. Blood Cells, Molecules, and Diseases.2000;26(5). CrossRef
  35. Role of glutathione peroxidase 1 in breast cancer. loss of heterozygosity and allelic differences in the response to selenium Hu YJ, Diamond AM. Cancer Res.2003;63:3347-3351.
  36. Association between genetic variants in glutathione peroxidase 1 gene and risk of prostate cancer: a meta-analysis Liwei Liu, Wei Zhang, Ruifa Han, Chunyu Liu. Molecular Biology Reports.2012;39(9). CrossRef
  37. GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis Hu Jia, Zhou Guo-Wu, Wang Ning, Wang Ya-Jie. Breast Cancer Research and Treatment.2010;124(2). CrossRef
  38. GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis Chen Jiawei, Cao Qiang, Qin Chao, Shao Pengfei, Wu Yilong, Wang Meilin, Zhang Zhengdong, Yin Changjun. Journal of Cancer Research and Clinical Oncology.2011;137(10). CrossRef
  39. Association between Polymorphisms in Glutathione Peroxidase and Selenoprotein P Genes, Glutathione Peroxidase Activity, HRT Use and Breast Cancer Risk Méplan Catherine, Dragsted Lars Ove, Ravn-Haren Gitte, Tjønneland Anne, Vogel Ulla, Hesketh John. PLoS ONE.2013;8(9). CrossRef
  40. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study Ravn-Haren Gitte, Olsen Anja, Tjønneland Anne, Dragsted Lars O., Nexø Bjørn A., Wallin Håkan, Overvad Kim, Raaschou-Nielsen Ole, Vogel Ulla. Carcinogenesis.2005;27(4). CrossRef
  41. Lipid peroxidation and glutathione peroxidase activity relationship in breast cancer depends on functional polymorphism of GPX1 Jablonska Ewa, Gromadzinska Jolanta, Peplonska Beata, Fendler Wojciech, Reszka Edyta, Krol Magdalena B., Wieczorek Edyta, Bukowska Agnieszka, Gresner Peter, Galicki Michal, Zambrano Quispe Oskar, Morawiec Zbigniew, Wasowicz Wojciech. BMC Cancer.2015;15(1). CrossRef
  42. Frequency of polymorphisms pro198leu in GPX-1 gene and ile58thr in MnSOD gene in the altitude Ecuadorian population with bladder cancer Paz-y-Mino M J, Munoz A, Lopez-Cortes . Oncology Research.2010;18(8):395-400.
  43. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, et al . Cancer Res.2000;60(22):6381-6383.
  44. Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry Knight J. A.. Cancer Epidemiology Biomarkers & Prevention.2004;13(1). CrossRef
  45. No association between GPX1 Pro198Leu and breast cancer risk Cox DG, Hankinson SE, Kraft P, Hunter DJ. Cancer Epidemiol Biomarkers Prev.2004;13:1821-1822.
  46. Selenoprotein Gene Variants, Toenail Selenium Levels, and Risk for Advanced Prostate Cancer Geybels Milan S., van den Brandt Piet A., Schouten Leo J., van Schooten Frederik J., van Breda Simone G., Rayman Margaret P., Green Fiona R., Verhage Bas A. J.. JNCI: Journal of the National Cancer Institute.2014;106(3). CrossRef
  47. CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia Taspinar M, Aydos SE, Comez O, Elhan AH, Karabulut HG, et al . Swiss Med Wkly.2008;138(1-2):12-17.
  48. Variations in glutathione-S-transferase genes influence risk of chronic myeloid leukemia Özten Nur, Sunguroğlu Asuman, Bosland Maarten C.. Hematological Oncology.2011;30(3). CrossRef
  49. Polymorphic Variation in Glutathione-S-transferase Genes and Risk of Chronic Myeloid Leukaemia in the Kashmiri Population Bhat Gulzar, Bhat Ashaqullah, Wani Aadil, Sadiq Nida, Jeelani Samoon, Kaur Rajinder, Masood Akbar, Ganai Bashir. Asian Pacific Journal of Cancer Prevention.2012;13(1). CrossRef
  50. Glutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemia He Hai-rong, Zhang Xiao-xia, Sun Jin-yue, Hu Sa-sa, Ma Ying, Dong Ya-lin, Lu Jun. Tumor Biology.2014;35(6). CrossRef
  51. Risk Effects of GST Gene Polymorphisms in Patients with Acute Myeloid Leukemia: A Prospective Study Zhou Lei, Zhu Yan-Yun, Zhang Xiao-Dong, Li Yang, Liu Zhuo-Gang. Asian Pacific Journal of Cancer Prevention.2013;14(6). CrossRef
  52. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms, evidence of a lack of association in Caucasians and African Americans Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, et al . Cancer Res. 1998;58:65-70..1998;58:65-70.
  53. Myeloperoxidase-enhanced formation of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a] pyrene adducts in lung tissue in vitro: a role of pulmonary inflammation in the bioactivation of a procarcinogen Petruska Janet M., Mosebrook D.Randolph, Jakab George J., Trush Michael A.. Carcinogenesis.1992;13(7). CrossRef
  54. Biosynthesis, processing, and sorting of human myeloperoxidase Hansson Markus, Olsson Inge, Nauseef William M.. Archives of Biochemistry and Biophysics.2006;445(2). CrossRef
  55. Role ofNQO1,MPO andCYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia Krajinovic Maja, Sinnett Hugues, Richer Chantal, Labuda Damian, Sinnett Daniel. International Journal of Cancer.2001;97(2). CrossRef
  56. Metabolic Enzyme Polymorphisms and Susceptibility to Acute Leukemia in Adults Morgan Gareth J., Smith Martyn T.. American Journal of PharmacoGenomics.2002;2(2). CrossRef
  57. Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking and risk of post-menopausal breast cancer Yang J., Ambrosone C. B., Hong C.-C., Ahn J., Rodriguez C., Thun M. J., Calle E. E.. Carcinogenesis.2007;28(6). CrossRef
  58. Genetic variants of myeloperoxidase and catechol-O-methyltransferase and breast cancer risk Lin S-C, Chou Y-C, Wu M-H, Wu C-C, Lin W-Y, Yu C-P, Yu J-C, You S-L, Chen C-J, Sun C-A. European Journal of Cancer Prevention.2005;14(3). CrossRef
  59. Point myeloperoxidase −463G→A polymorphism and lung cancer risk Feyler A, Voho A, Bouchardy C. Cancer Epidemiol Biomarkers.2002;11:1550-1554.
  60. Iron intake, oxidative stress-related genes ( MnSOD and MPO ) and prostate cancer risk in CARET cohort Choi Ji-Yeob, Neuhouser Marian L., Barnett Matt J., Hong Chi-Chen, Kristal Alan R., Thornquist Mark D., King Irena B., Goodman Gary E., Ambrosone Christine B.. Carcinogenesis.2008;29(5). CrossRef

Content

Abstract Introduction Materials and Methods Results Discussion Acknowledgments References

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright

© Asian Pacific Journal of Cancer Biology , 2021

Author Details

Sailaja Kagita
Department of Genetics and Molecular Biology, KIMS-ICON Hospital, Sheelanagar, Visakhapatnam, Andhra Pradesh, India
kagitasa@gmail.com

Raghunadharao Digumarti
Department of Medical Oncology, KIMS-ICON Hospital, Sheelanagar, Visakhapatnam, Andhra Pradesh, India

Sadhashivudu Gundeti
Department of Medical Oncology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India

How to Cite

1.
Kagita S, Digumarti R, Gundeti S. Role of Antioxidant Gene Polymorphisms in Risk and Prognosis of Chronic Myeloid Leukemia. apjcb [Internet]. 21Mar.2021 [cited 23Nov.2024];6(1):27-6. Available from: http://waocp.com/journal/index.php/apjcb/article/view/623
  • Abstract viewed - 0 times
  • PDF (FULL TEXT) downloaded - 0 times
  • Xml downloaded - 0 times